IRGD-Decorated Polymeric Nanoparticles for the Efficient Delivery of Vandetanib to Hepatocellular Carcinoma: Preparation and in Vitro and in Vivo Evaluation

ACS Applied Materials and Interfaces

Volumn 8, Issue 30, 2016, Pages 19228-19237

  Wang, Jianguo ^a   Wang, Hangxiang ^a   Li, Jie ^a   Liu, Zhikun ^a   Xie, Haiyang ^a   Wei, Xuyong ^a   Lu, Di ^a   Zhuang, Runzhou ^a   Xu, Xiao ^a   Zheng, Shusen ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

cancer nanomedicine; hepatocellular carcinoma; molecularly targeted agents; self assembly; targeted delivery

Indexed keywords

BIOCHEMISTRY; BLOCK COPOLYMERS; CYTOTOXICITY; DISEASES; ENZYMES; LACTIC ACID; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; ONCOLOGY; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; SELF ASSEMBLY; TUMORS;

AMPHIPHILIC BLOCK COPOLYMERS; ANTI-CANCER THERAPIES; CYTOTOXIC ACTIVITIES; HEPATOCELLULAR CARCINOMA; INTRAVENOUS ADMINISTRATION; POLYMERIC NANOPARTICLES; SYSTEMIC ADMINISTRATION; TARGETED DELIVERY;

POLYMERS;

N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; NANOPARTICLE; PIPERIDINE DERIVATIVE; POLYMER; QUINAZOLINE DERIVATIVE;

ANIMAL; CELL SURVIVAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; LIVER CELL CARCINOMA; LIVER TUMOR; MOUSE; TUMOR CELL LINE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; LIVER NEOPLASMS; MICE; NANOPARTICLES; PIPERIDINES; POLYMERS; QUINAZOLINES;

EID: 84982672517     PISSN: 19448244     EISSN: 19448252     Source Type: Journal    
DOI: 10.1021/acsami.6b03166     Document Type: Article

References (56)

1. Hanahan, D.; Weinberg, R. A. Hallmarks of Cancer: The Next Generation Cell 2011, 144, 646-674 10.1016/j.cell.2011.02.013
2. Dancey, J. E.; Chen, H. X. Strategies for Optimizing Combinations of Molecularly Targeted Anticancer Agents Nat. Rev. Drug Discovery 2006, 5, 649-659 10.1038/nrd2089
3. Llovet, J. M.; Bruix, J. Molecular Targeted Therapies in Hepatocellular Carcinoma Hepatology 2008, 48, 1312-1327 10.1002/hep.22506
4. Vong, L. B.; Yoshitomi, T.; Matsui, H.; Nagasaki, Y. Development of an Oral Nanotherapeutics Using Redox Nanoparticles for Treatment of Colitis-Associated Colon Cancer Biomaterials 2015, 55, 54-63 10.1016/j.biomaterials.2015.03.037
5. Chen, F.; Zhang, J.; Wang, L.; Wang, Y.; Chen, M. Tumor Phe-Triggered Charge-Reversal and Redox-Responsive Nanoparticles for Docetaxel Delivery in Hepatocellular Carcinoma Treatment Nanoscale 2015, 7, 15763-15779 10.1039/C5NR04612B
6. Huang, M.; Shen, A.; Ding, J.; Geng, M. Molecularly Targeted Cancer Therapy: Some Lessons from the Past Decade Trends Pharmacol. Sci. 2014, 35, 41-50 10.1016/j.tips.2013.11.004
7. Bertrand, N.; Wu, J.; Xu, X.; Kamaly, N.; Farokhzad, O. C. Cancer Nanotechnology: The Impact of Passive and Active Targeting in the Era of Modern Cancer Biology Adv. Drug Delivery Rev. 2014, 66, 2-25 10.1016/j.addr.2013.11.009
8. Mohanty, C.; Acharya, S.; Mohanty, A. K.; Dilnawaz, F.; Sahoo, S. K. Curcumin-Encapsulated Mepeg/Pcl Diblock Copolymeric Micelles: A Novel Controlled Delivery Vehicle for Cancer Therapy Nanomedicine (London, U. K.) 2010, 5, 433-449 10.2217/nnm.10.9
9. Jiang, C.; Wang, H.; Zhang, X.; Sun, Z.; Wang, F.; Cheng, J.; Xie, H.; Yu, B.; Zhou, L. Deoxycholic Acid-Modified Chitooligosaccharide/Mpeg-Pdlla Mixed Micelles Loaded with Paclitaxel for Enhanced Antitumor Efficacy Int. J. Pharm. 2014, 475, 60-68 10.1016/j.ijpharm.2014.08.037
10. Owens, D. E., 3rd; Peppas, N. A. Opsonization, Biodistribution, and Pharmacokinetics of Polymeric Nanoparticles Int. J. Pharm. 2006, 307, 93-102 10.1016/j.ijpharm.2005.10.010
11. Kai, M. P.; Keeler, A. W.; Perry, J. L.; Reuter, K. G.; Luft, J. C.; O'Neal, S. K.; Zamboni, W. C.; DeSimone, J. M. Evaluation of Drug Loading, Pharmacokinetic Behavior, and Toxicity of a Cisplatin-Containing Hydrogel Nanoparticle J. Controlled Release 2015, 204, 70-77 10.1016/j.jconrel.2015.03.001
12. Wang, H.; Xie, H.; Wang, J.; Wu, J.; Ma, X.; Li, L.; Wei, X.; Ling, Q.; Song, P.; Zhou, L.; Xu, X.; Zheng, S. Self-Assembling Prodrugs by Precise Programming of Molecular Structures That Contribute Distinct Stability, Pharmacokinetics, and Antitumor Efficacy Adv. Funct. Mater. 2015, 25, 4956-4965 10.1002/adfm.201501953
13. Karve, S.; Werner, M. E.; Sukumar, R.; Cummings, N. D.; Copp, J. A.; Wang, E. C.; Li, C.; Sethi, M.; Chen, R. C.; Pacold, M. E.; Wang, A. Z. Revival of the Abandoned Therapeutic Wortmannin by Nanoparticle Drug Delivery Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 8230-8235 10.1073/pnas.1120508109
14. Wang, H.; Xie, H.; Wu, J.; Wei, X.; Zhou, L.; Xu, X.; Zheng, S. Structure-Based Rational Design of Prodrugs to Enable Their Combination with Polymeric Nanoparticle Delivery Platforms for Enhanced Antitumor Efficacy Angew. Chem., Int. Ed. 2014, 53, 11532-11537 10.1002/anie.201406685
15. Guo, S. T.; Lin, C. M.; Xu, Z. H.; Miao, L.; Wang, Y. H.; Huang, L. Co-Delivery of Cisplatin and Rapamycin for Enhanced Anticancer Therapy through Synergistic Effects and Microenvironment Modulation ACS Nano 2014, 8, 4996-5009 10.1021/nn5010815
16. Chau, N. G.; Haddad, R. I. Vandetanib for the Treatment of Medullary Thyroid Cancer Clin. Cancer Res. 2013, 19, 524-529 10.1158/1078-0432.CCR-12-2353
17. Falchook, G. S.; Ordonez, N. G.; Bastida, C. C.; Stephens, P. J.; Miller, V. A.; Gaido, L.; Jackson, T.; Karp, D. D. Effect of the Ret Inhibitor Vandetanib in a Patient with Ret Fusion-Positive Metastatic Non-Small-Cell Lung Cancer J. Clin. Oncol. 2016, 34, e141-144 10.1200/JCO.2013.50.5016
18. Azad, A. A.; Beardsley, E. K.; Hotte, S. J.; Ellard, S. L.; Klotz, L.; Chin, J.; Kollmannsberger, C.; Mukherjee, S. D.; Chi, K. N. A Randomized Phase Ii Efficacy and Safety Study of Vandetanib (Zd6474) in Combination with Bicalutamide Versus Bicalutamide Alone in Patients with Chemotherapy Naive Castration-Resistant Prostate Cancer Invest. New Drugs 2014, 32, 746-752 10.1007/s10637-014-0091-8
19. Coleman, R. L.; Moon, J.; Sood, A. K.; Hu, W.; Delmore, J. E.; Bonebrake, A. J.; Anderson, G. L.; Chambers, S. K.; Markman, M. Randomised Phase Ii Study of Docetaxel Plus Vandetanib Versus Docetaxel Followed by Vandetanib in Patients with Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: Swog S0904 Eur. J. Cancer 2014, 50, 1638-1648 10.1016/j.ejca.2014.03.005
20. Hsu, C.; Yang, T. S.; Huo, T. I.; Hsieh, R. K.; Yu, C. W.; Hwang, W. S.; Hsieh, T. Y.; Huang, W. T.; Chao, Y.; Meng, R.; Cheng, A. L. Vandetanib in Patients with Inoperable Hepatocellular Carcinoma: A Phase Ii, Randomized, Double-Blind, Placebo-Controlled Study J. Hepatol. 2012, 56, 1097-1103 10.1016/j.jhep.2011.12.013
21. Iwamoto, H.; Torimura, T.; Nakamura, T.; Hashimoto, O.; Inoue, K.; Kurogi, J.; Niizeki, T.; Kuwahara, R.; Abe, M.; Koga, H.; Yano, H.; Kerbel, R. S.; Ueno, T.; Sata, M. Metronomic S-1 Chemotherapy and Vandetanib: An Efficacious and Nontoxic Treatment for Hepatocellular Carcinoma Neoplasia 2011, 13, 187-197 10.1593/neo.101186
22. Inoue, K.; Torimura, T.; Nakamura, T.; Iwamoto, H.; Masuda, H.; Abe, M.; Hashimoto, O.; Koga, H.; Ueno, T.; Yano, H.; Sata, M. Vandetanib, an Inhibitor of Vegf Receptor-2 and Egf Receptor, Suppresses Tumor Development and Improves Prognosis of Liver Cancer in Mice Clin. Cancer Res. 2012, 18, 3924-3933 10.1158/1078-0432.CCR-11-2041
23. Nicolas, J.; Mura, S.; Brambilla, D.; Mackiewicz, N.; Couvreur, P. Design, Functionalization Strategies and Biomedical Applications of Targeted Biodegradable/Biocompatible Polymer-Based Nanocarriers for Drug Delivery Chem. Soc. Rev. 2013, 42, 1147-1235 10.1039/C2CS35265F
24. Yao, Y.; Zhang, M.; Liu, T.; Zhou, J.; Gao, Y.; Wen, Z.; Guan, J.; Zhu, J.; Lin, Z.; He, D. Perfluorocarbon-Encapsulated Plga-Peg Emulsions as Enhancement Agents for Highly Efficient Reoxygenation to Cell and Organism ACS Appl. Mater. Interfaces 2015, 7, 18369-18378 10.1021/acsami.5b04226
25. Rabanel, J. M.; Faivre, J.; Tehrani, S. F.; Lalloz, A.; Hildgen, P.; Banquy, X. Effect of the Polymer Architecture on the Structural and Biophysical Properties of Peg-Pla Nanoparticles ACS Appl. Mater. Interfaces 2015, 7, 10374-10385 10.1021/acsami.5b01423
26. Sugahara, K. N.; Teesalu, T.; Karmali, P. P.; Kotamraju, V. R.; Agemy, L.; Girard, O. M.; Hanahan, D.; Mattrey, R. F.; Ruoslahti, E. Tissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors Cancer Cell 2009, 16, 510-520 10.1016/j.ccr.2009.10.013
27. Lee, S. W.; Yun, M. H.; Jeong, S. W.; In, C. H.; Kim, J. Y.; Seo, M. H.; Pai, C. M.; Kim, S. O. Development of Docetaxel-Loaded Intravenous Formulation, Nanoxel-Pm Using Polymer-Based Delivery System J. Controlled Release 2011, 155, 262-271 10.1016/j.jconrel.2011.06.012
28. Cabral, H.; Matsumoto, Y.; Mizuno, K.; Chen, Q.; Murakami, M.; Kimura, M.; Terada, Y.; Kano, M. R.; Miyazono, K.; Uesaka, M.; Nishiyama, N.; Kataoka, K. Accumulation of Sub-100 Nm Polymeric Micelles in Poorly Permeable Tumours Depends on Size Nat. Nanotechnol. 2011, 6, 815-823 10.1038/nnano.2011.166
29. Perrault, S. D.; Walkey, C.; Jennings, T.; Fischer, H. C.; Chan, W. C. Mediating Tumor Targeting Efficiency of Nanoparticles through Design Nano Lett. 2009, 9, 1909-1915 10.1021/nl900031y
30. Berge, M.; Allanic, D.; Bonnin, P.; de Montrion, C.; Richard, J.; Suc, M.; Boivin, J. F.; Contreres, J. O.; Lockhart, B. P.; Pocard, M.; Levy, B. I.; Tucker, G. C.; Tobelem, G.; Merkulova-Rainon, T. Neuropilin-1 Is Upregulated in Hepatocellular Carcinoma and Contributes to Tumour Growth and Vascular Remodelling J. Hepatol. 2011, 55, 866-875 10.1016/j.jhep.2011.01.033
31. Sugahara, K. N.; Braun, G. B.; de Mendoza, T. H.; Kotamraju, V. R.; French, R. P.; Lowy, A. M.; Teesalu, T.; Ruoslahti, E. Tumor-Penetrating Irgd Peptide Inhibits Metastasis Mol. Cancer Ther. 2015, 14, 120-128 10.1158/1535-7163.MCT-14-0366
32. Schmithals, C.; Koberle, V.; Korkusuz, H.; Pleli, T.; Kakoschky, B.; Augusto, E. A.; Ibrahim, A. A.; Arencibia, J. M.; Vafaizadeh, V.; Groner, B.; Korf, H. W.; Kronenberger, B.; Zeuzem, S.; Vogl, T. J.; Waidmann, O.; Piiper, A. Improving Drug Penetrability with Irgd Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma Cancer Res. 2015, 75, 3147-3154 10.1158/0008-5472.CAN-15-0395
33. Xie, H.; Xu, X.; Chen, J.; Li, L.; Wang, J.; Fang, T.; Zhou, L.; Wang, H.; Zheng, S. Rational Design of Multifunctional Small-Molecule Prodrugs for Simultaneous Suppression of Cancer Cell Growth and Metastasis in Vitro and in Vivo Chem. Commun. (Cambridge, U. K.) 2016, 52, 5601-5604 10.1039/C5CC10367C
34. Danial, N. N. Bcl-2 Family Proteins: Critical Checkpoints of Apoptotic Cell Death Clin. Cancer Res. 2007, 13, 7254-7263 10.1158/1078-0432.CCR-07-1598
35. Bao, W.; Liu, R.; Wang, Y.; Wang, F.; Xia, G.; Zhang, H.; Li, X.; Yin, H.; Chen, B. Plga-Pll-Peg-Tf-Based Targeted Nanoparticles Drug Delivery System Enhance Antitumor Efficacy Via Intrinsic Apoptosis Pathway Int. J. Nanomed. 2015, 10, 557-566 10.2147/IJN.S75090
36. Kastan, M. B.; Bartek, J. Cell-Cycle Checkpoints and Cancer Nature 2004, 432, 316-323 10.1038/nature03097
37. Satyanarayana, A.; Kaldis, P. Mammalian Cell-Cycle Regulation: Several Cdks, Numerous Cyclins and Diverse Compensatory Mechanisms Oncogene 2009, 28, 2925-2939 10.1038/onc.2009.170
38. Arora, S.; Tyagi, N.; Bhardwaj, A.; Rusu, L.; Palanki, R.; Vig, K.; Singh, S. R.; Singh, A. P.; Palanki, S.; Miller, M. E.; Carter, J. E.; Singh, S. Silver Nanoparticles Protect Human Keratinocytes against Uvb Radiation-Induced DNA Damage and Apoptosis: Potential for Prevention of Skin Carcinogenesis Nanomedicine 2015, 11, 1265-1275 10.1016/j.nano.2015.02.024
39. Tian, Z.; Shen, J.; Moseman, A. P.; Yang, Q.; Yang, J.; Xiao, P.; Wu, E.; Kohane, I. S. Dulxanthone a Induces Cell Cycle Arrest and Apoptosis Via up-Regulation of P53 through Mitochondrial Pathway in Hepg2 Cells Int. J. Cancer 2008, 122, 31-38 10.1002/ijc.23048
40. Dutto, I.; Tillhon, M.; Cazzalini, O.; Stivala, L. A.; Prosperi, E. Biology of the Cell Cycle Inhibitor P21(Cdkn1a): Molecular Mechanisms and Relevance in Chemical Toxicology Arch. Toxicol. 2015, 89, 155-178 10.1007/s00204-014-1430-4
41. Xiong, Y.; Hannon, G. J.; Zhang, H.; Casso, D.; Kobayashi, R.; Beach, D. P21 Is a Universal Inhibitor of Cyclin Kinases Nature 1993, 366, 701-704 10.1038/366701a0
42. Anitua, E.; Pelacho, B.; Prado, R.; Aguirre, J. J.; Sanchez, M.; Padilla, S.; Aranguren, X. L.; Abizanda, G.; Collantes, M.; Hernandez, M.; Perez-Ruiz, A.; Penuelas, I.; Orive, G.; Prosper, F. Infiltration of Plasma Rich in Growth Factors Enhances in Vivo Angiogenesis and Improves Reperfusion and Tissue Remodeling after Severe Hind Limb Ischemia J. Controlled Release 2015, 202, 31-39 10.1016/j.jconrel.2015.01.029
43. Shen, G.; Li, Y.; Du, T.; Shi, G.; Dai, L.; Chen, X.; Zheng, R.; Li, W.; Su, X.; Zhang, S.; Wei, Y.; Yang, S.; Deng, H. Sklb1002, a Novel Inhibitor of Vegf Receptor 2 Signaling, Induces Vascular Normalization to Improve Systemically Administered Chemotherapy Efficacy Neoplasma 2012, 59, 486-493 10.4149/neo-2012-062
44. Carmeliet, P.; Jain, R. K. Angiogenesis in Cancer and Other Diseases Nature 2000, 407, 249-257 10.1038/35025220
45. Wang, R.; Zhao, N.; Li, S.; Fang, J. H.; Chen, M. X.; Yang, J.; Jia, W. H.; Yuan, Y.; Zhuang, S. M. Microrna-195 Suppresses Angiogenesis and Metastasis of Hepatocellular Carcinoma by Inhibiting the Expression of Vegf, Vav2, and Cdc42 Hepatology 2013, 58, 642-653 10.1002/hep.26373
46. Kim, Y. J.; Bae, J.; Shin, T. H.; Kang, S. H.; Jeong, M.; Han, Y.; Park, J. H.; Kim, S. K.; Kim, Y. S. Immunoglobulin Fc-Fused, Neuropilin-1-Specific Peptide Shows Efficient Tumor Tissue Penetration and Inhibits Tumor Growth Via Anti-Angiogenesis J. Controlled Release 2015, 216, 56-68 10.1016/j.jconrel.2015.08.016
47. Sugahara, K. N.; Teesalu, T.; Karmali, P. P.; Kotamraju, V. R.; Agemy, L.; Greenwald, D. R.; Ruoslahti, E. Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs Science 2010, 328, 1031-1035 10.1126/science.1183057
48. Kadonosono, T.; Yamano, A.; Goto, T.; Tsubaki, T.; Niibori, M.; Kuchimaru, T.; Kizaka-Kondoh, S. Cell Penetrating Peptides Improve Tumor Delivery of Cargos through Neuropilin-1-Dependent Extravasation J. Controlled Release 2015, 201, 14-21 10.1016/j.jconrel.2015.01.011
49. Alberici, L.; Roth, L.; Sugahara, K. N.; Agemy, L.; Kotamraju, V. R.; Teesalu, T.; Bordignon, C.; Traversari, C.; Rizzardi, G. P.; Ruoslahti, E. De Novo Design of a Tumor-Penetrating Peptide Cancer Res. 2013, 73, 804-812 10.1158/0008-5472.CAN-12-1668
50. Ruoslahti, E. Peptides as Targeting Elements and Tissue Penetration Devices for Nanoparticles Adv. Mater. 2012, 24, 3747-3756 10.1002/adma.201200454
51. Desgrosellier, J. S.; Cheresh, D. A. Integrins in Cancer: Biological Implications and Therapeutic Opportunities Nat. Rev. Cancer 2010, 10, 9-22 10.1038/nrc2748
52. Wang, K.; Zhang, X.; Liu, Y.; Liu, C.; Jiang, B.; Jiang, Y. Tumor Penetrability and Anti-Angiogenesis Using Irgd-Mediated Delivery of Doxorubicin-Polymer Conjugates Biomaterials 2014, 35, 8735-8747 10.1016/j.biomaterials.2014.06.042
53. Gu, G.; Gao, X.; Hu, Q.; Kang, T.; Liu, Z.; Jiang, M.; Miao, D.; Song, Q.; Yao, L.; Tu, Y.; Pang, Z.; Chen, H.; Jiang, X.; Chen, J. The Influence of the Penetrating Peptide Irgd on the Effect of Paclitaxel-Loaded Mt1-Af7p-Conjugated Nanoparticles on Glioma Cells Biomaterials 2013, 34, 5138-5148 10.1016/j.biomaterials.2013.03.036
54. Sugahara, K. N.; Scodeller, P.; Braun, G. B.; de Mendoza, T. H.; Yamazaki, C. M.; Kluger, M. D.; Kitayama, J.; Alvarez, E.; Howell, S. B.; Teesalu, T.; Ruoslahti, E.; Lowy, A. M. A Tumor-Penetrating Peptide Enhances Circulation-Independent Targeting of Peritoneal Carcinomatosis J. Controlled Release 2015, 212, 59-69 10.1016/j.jconrel.2015.06.009
55. Sha, H.; Zou, Z.; Xin, K.; Bian, X.; Cai, X.; Lu, W.; Chen, J.; Chen, G.; Huang, L.; Blair, A. M.; Cao, P.; Liu, B. Tumor-Penetrating Peptide Fused Egfr Single-Domain Antibody Enhances Cancer Drug Penetration into 3d Multicellular Spheroids and Facilitates Effective Gastric Cancer Therapy J. Controlled Release 2015, 200, 188-200 10.1016/j.jconrel.2014.12.039
56. Kummar, S.; Chen, H. X.; Wright, J.; Holbeck, S.; Millin, M. D.; Tomaszewski, J.; Zweibel, J.; Collins, J.; Doroshow, J. H. Utilizing Targeted Cancer Therapeutic Agents in Combination: Novel Approaches and Urgent Requirements Nat. Rev. Drug Discovery 2010, 9, 843-856 10.1038/nrd3216